ABBVIE INC (4AB.DE) Stock Price, Forecast & Analysis
FRA:4AB • US00287Y1091
4AB.DE Key Statistics, Chart & Performance
The current stock price of 4AB.DE is 191.2 EUR. In the past month the price increased by 3.02%. In the past year, price decreased by -1.13%.
4AB.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 4AB.DE. When comparing the yearly performance of all stocks, 4AB.DE is a bad performer in the overall market: 77.32% of all stocks are doing better.
4AB.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE. Both the profitability and the financial health of 4AB.DE get a neutral evaluation. Nothing too spectacular is happening here.
4AB.DE Financial Highlights
Over the last trailing twelve months 4AB.DE reported a non-GAAP Earnings per Share(EPS) of 8.5. The EPS decreased by -1.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.94% | ||
| ROA | 1.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
4AB.DE Forecast & Estimates
37 analysts have analysed 4AB.DE and the average price target is 213.99 EUR. This implies a price increase of 11.92% is expected in the next year compared to the current price of 191.2.
For the next year, analysts expect an EPS growth of 45.22% and a revenue growth 9.84% for 4AB.DE
4AB.DE Ownership
4AB.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.35 | 44.705B | ||
| 1AE | ARGENX SE | 28.3 | 44.618B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.471B | ||
| ABVX | ABIVAX SA | N/A | 8.888B | ||
| 2X1 | ABIVAX SA | N/A | 8.872B | ||
| GLPG | GALAPAGOS NV | N/A | 1.891B | ||
| GXE | GALAPAGOS NV | N/A | 1.887B | ||
| IVA | INVENTIVA SA | N/A | 1.16B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| NANO | NANOBIOTIX | N/A | 1.055B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 4AB.DE
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Company Info
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS US
Employees: 55000
Phone: 18479327900
ABBVIE INC / 4AB.DE FAQ
What does ABBVIE INC do?
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
What is the current price of 4AB stock?
The current stock price of 4AB.DE is 191.2 EUR. The price increased by 0.31% in the last trading session.
Does ABBVIE INC pay dividends?
ABBVIE INC (4AB.DE) has a dividend yield of 3.04%. The yearly dividend amount is currently 5.26.
What is the ChartMill technical and fundamental rating of 4AB stock?
4AB.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about ABBVIE INC (4AB.DE) stock?
37 analysts have analysed 4AB.DE and the average price target is 213.99 EUR. This implies a price increase of 11.92% is expected in the next year compared to the current price of 191.2.
Would investing in ABBVIE INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 4AB.DE.